Compare KNX & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNX | MDGL |
|---|---|---|
| Founded | 1989 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 12.8B |
| IPO Year | 2010 | 2005 |
| Metric | KNX | MDGL |
|---|---|---|
| Price | $67.65 | $534.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 12 |
| Target Price | $65.00 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 2.7M | 214.6K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,469,689,000.00 | $180,133,000.00 |
| Revenue This Year | $6.91 | $58.39 |
| Revenue Next Year | $7.56 | $48.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.80 | N/A |
| 52 Week Low | $38.63 | $393.61 |
| 52 Week High | $82.86 | $615.00 |
| Indicator | KNX | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 48.19 |
| Support Level | $66.86 | $499.26 |
| Resistance Level | $73.97 | $545.13 |
| Average True Range (ATR) | 2.42 | 17.53 |
| MACD | 0.22 | 0.24 |
| Stochastic Oscillator | 49.93 | 43.24 |
Knight-Swift Transportation is the largest full-truckload carrier in the US, with a diversified transportation offering. Roughly 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 63% and less than truckload 19%. Truck brokerage and other asset-light logistics services make up 8% of revenue, with intermodal near 5%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue is from services offered to shippers and third-party truckers, including equipment maintenance and leasing.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.